Furthermore, Osimertinib has been recommended for EGFR sensitizing (19del/L858R) and EGFR T790M mutation‐positive advanced NSCLC in the 2023 National Comprehensive Cancer Network guidelines,6 as well as in the European Society of Medical Oncology (ESMO),7 the Chinese Society of Clinical Oncology (CSCO),8, 9 and the Chinese Medical Association.10 Here, EGFR is linked to non-small cell lung carcinoma.